FISH and Cytogenetic Analysis of MM and Related Disorders
| Patient No. . | Age/Sex . | M Protein . | Materials . | Plasma Cells . | G-Banded Karyotype* . | Metaphase FISH . | Interphase FISH . | Split Pattern‡ . | |
|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | s/Total . | Donor† . | s/Total . | . |
| . | . | . | . | . | . | (%) . | . | (%) . | . |
| MM | |||||||||
| 1 | 65/F | A, λ | BM | 95.0 | t(8; 14) | 3/4 (75) | 8q24 | 89/100 (89) | YYR |
| 2 | 68/M | BJ, κ | BM | 90.8 | t(8; 22) | 6/7 (86) | 16q24 | 56/100 (56) | YGR |
| 3 | 72/F | BJ, κ | BM | 86.4 | 46,XX[25] | 0/25 (0) | 8/100 (8) | YGR | |
| 4 | 82/M | G, κ | BM | 71.2 | Abnormal | 0/22 (0) | 22/100 (22) | YGR | |
| 5 | 79/F | G, κ | BM | 60.8 | Abnormal | 4/20 (20) | Unknown | 16/100 (16) | YGR |
| 6 | 49/M | A, κ | BM | 54.0 | 46,XY[8] | 0/3 (0) | 12/100 (12) | YGR | |
| 7 | 55/M | G, λ | BM | 53.2 | 46,XY[8] | 0/8 (0) | 19/100 (19) | YR | |
| 8 | 83/F | G, κ | BM | 50.8 | 46,XX[2] | ND | 13/100 (13) | YGR | |
| 9 | 77/M | G, κ | BM | 45.6 | Abnormal | 2/16 (13) | Unknown | 25/100 (25) | YGR |
| 10 | 70/F | G, κ | BM | 44.4 | 46,XX[10] | 1/11 (9) | 11q13 | 38/100 (38) | YR |
| 11 | 42/M | BJ, λ | BM | 44.4 | 14q+ | 7/7 (100) | 7q32.1 | 60/100 (60) | GR |
| 12 | 50/M | G, λ | BM | 39.0 | 14q+ | 1/22 (5) | Unknown | 18/100 (18) | YGR |
| 13 | 54/M | A, λ | BM | 36.8 | ND | 1/6 (17) | Unknown | 24/100 (24) | YGR |
| 14 | 55/M | BJ, λ | BM | 34.2 | Abnormal | 0/10 (0) | 10/100 (10) | YGR | |
| 15 | 59/F | G, κ | BM | 32.0 | Abnormal | 0/17 (0) | 30/100 (30) | YGR | |
| 16 | 63/M | A, κ | BM | 30.0 | ND | 1/14 (7) | Unknown | 7/100 (7) | YGR |
| 17 | 68/M | G, κ | BM | 28.8 | 46,XY[4] | 0/6 (0) | 24/100 (24) | YGR | |
| 18 | 39/M | BJ, κ | BM | 26.0 | 46,XY[13] | 3/18 (17) | 8q24 | 22/100 (22) | YGR |
| 19 | 62/M | G, λ | BM | 24.0 | Abnormal | 5/18 (28) | Unknown | 24/200 (12) | YGR |
| 20 | 66/M | G, κ | BM | 21.6 | 46,XY[20] | 2/24 (8) | 18q21 | 19/100 (19) | YGR |
| 21 | 67/F | G, κ | BM | 19.6 | 46,XX[20] | 1/14 (7) | Unknown | 10/100 (10) | YGR |
| 22 | 65/M | G, λ | BM | 19.2 | 46,XY[5] | ND | 17/100 (17) | YGR | |
| 23 | 76/F | G, λ | BM | 16.0 | 46,XX[5] | 2/20 (10) | Unknown | 10/100 (10) | YGR |
| 25 | 63/M | G, κ | BM | 15.2 | 46,XY[10] | 2/21 (10) | Unknown | 14/100 (14) | YGR |
| 24 | 61/F | G, κ | BM | 15.0 | 46,XX[20] | 4/16 (25) | 18q21 | 17/100 (17) | YGR |
| 26 | 75/F | G, λ | BM | 13.8 | ND | 1/7 (14) | Unknown | 11/100 (11) | YGR |
| 27 | 44/F | G, κ | BM | 13.2 | 46,XX[20] | 0/31 (0) | 10/100 (10) | YGR | |
| 28 | 82/F | G, λ | PE | 88.1 | Abnormal | 0/11 (0) | 1/100 (1) | ||
| 29 | 70/F | G, κ | BM | 59.2 | 46,XX[7] | 0/8 (0) | 6/100 (6) | ||
| 30 | 62/F | G, κ | BM | 17.4 | 46,XX[3] | ND | 4/100 (4) | ||
| 40.6ρ | |||||||||
| 31 | 54/M | G, κ | BM | 44.0 | t(8; 22) | 0/5 (0) | Unevaluable1-155 | ||
| 32 | 75/M | G, λ | BM | 43.0 | ND | 0/10 (0) | 1/50 (2) | ||
| 33 | 73/F | G, κ | BM | 36.4 | ND | ND | 5/100 (5) | ||
| 34 | 74/M | G, κ | BM | 33.6 | 46,XY[20] | 0/20 | 1/100 (1) | ||
| 35 | 81/M | G, κ | BM | 20.8 | 46,XY[5] | 0/11 (0) | 4/100 (4) | ||
| 36 | 65/M | G, λ | BM | 15.8 | 46,XY[20] | 0/15 (0) | 5/100 (5) | ||
| 37 | 62/M | G, κ | BM | 15.6 | 46,XY[22] | 0/26 (0) | 3/100 (3) | ||
| 38 | 60/M | G, κ | BM | 12.0 | 46,XY[18] | 0/4 (0) | 4/100 (4) | ||
| Plasma cell leukemia | |||||||||
| 39 | 66/M | G, κ | BM | 84.4 | 46,XY[5] | 4/6 (67) | 11q13 | 55/100 (55) | YGR |
| 401-154 | 79/F | BJ, (nonsecretary) | PB | 80.0 | 11q− | 3/5 (60) | 11q13 | 13/100 (13) | YYGG |
| 41 | 62/M | G, κ | PB | 28.0 | ND | 2/3 (67) | 11q13 | 15/100 (15) | YGR |
| Plasmacytoma | |||||||||
| 42 | 71/F | G, λ | BM | 19.8 | 46,XX[20] | 1/12 (8) | 11q13 | 8/50 (16) | YGR |
| MGUS | |||||||||
| 43 | 73/M | G, κ | BM | 9.6 | ND | 0/10 (0) | 18/200 (9) | YGR | |
| 44 | 73/M | G, λ | BM | 5.6 | Abnormal | 2/13 (15) | Unknown | 11/100 (11) | YGR |
| 45 | 78/M | G, λ | BM | 4.8 | 46,XY[20] | 0/14 (0) | 8/100 (8) | YGR | |
| 46 | 71/F | G, λ | BM | 8.8 | 46,XX[12] | 0/24 (0) | 3/100 (3) | ||
| 47 | 80/F | G, κ | BM | 1.6 | 46,XX[20] | 0/30 (0) | 4/100 (4) | ||
| Patient No. . | Age/Sex . | M Protein . | Materials . | Plasma Cells . | G-Banded Karyotype* . | Metaphase FISH . | Interphase FISH . | Split Pattern‡ . | |
|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | s/Total . | Donor† . | s/Total . | . |
| . | . | . | . | . | . | (%) . | . | (%) . | . |
| MM | |||||||||
| 1 | 65/F | A, λ | BM | 95.0 | t(8; 14) | 3/4 (75) | 8q24 | 89/100 (89) | YYR |
| 2 | 68/M | BJ, κ | BM | 90.8 | t(8; 22) | 6/7 (86) | 16q24 | 56/100 (56) | YGR |
| 3 | 72/F | BJ, κ | BM | 86.4 | 46,XX[25] | 0/25 (0) | 8/100 (8) | YGR | |
| 4 | 82/M | G, κ | BM | 71.2 | Abnormal | 0/22 (0) | 22/100 (22) | YGR | |
| 5 | 79/F | G, κ | BM | 60.8 | Abnormal | 4/20 (20) | Unknown | 16/100 (16) | YGR |
| 6 | 49/M | A, κ | BM | 54.0 | 46,XY[8] | 0/3 (0) | 12/100 (12) | YGR | |
| 7 | 55/M | G, λ | BM | 53.2 | 46,XY[8] | 0/8 (0) | 19/100 (19) | YR | |
| 8 | 83/F | G, κ | BM | 50.8 | 46,XX[2] | ND | 13/100 (13) | YGR | |
| 9 | 77/M | G, κ | BM | 45.6 | Abnormal | 2/16 (13) | Unknown | 25/100 (25) | YGR |
| 10 | 70/F | G, κ | BM | 44.4 | 46,XX[10] | 1/11 (9) | 11q13 | 38/100 (38) | YR |
| 11 | 42/M | BJ, λ | BM | 44.4 | 14q+ | 7/7 (100) | 7q32.1 | 60/100 (60) | GR |
| 12 | 50/M | G, λ | BM | 39.0 | 14q+ | 1/22 (5) | Unknown | 18/100 (18) | YGR |
| 13 | 54/M | A, λ | BM | 36.8 | ND | 1/6 (17) | Unknown | 24/100 (24) | YGR |
| 14 | 55/M | BJ, λ | BM | 34.2 | Abnormal | 0/10 (0) | 10/100 (10) | YGR | |
| 15 | 59/F | G, κ | BM | 32.0 | Abnormal | 0/17 (0) | 30/100 (30) | YGR | |
| 16 | 63/M | A, κ | BM | 30.0 | ND | 1/14 (7) | Unknown | 7/100 (7) | YGR |
| 17 | 68/M | G, κ | BM | 28.8 | 46,XY[4] | 0/6 (0) | 24/100 (24) | YGR | |
| 18 | 39/M | BJ, κ | BM | 26.0 | 46,XY[13] | 3/18 (17) | 8q24 | 22/100 (22) | YGR |
| 19 | 62/M | G, λ | BM | 24.0 | Abnormal | 5/18 (28) | Unknown | 24/200 (12) | YGR |
| 20 | 66/M | G, κ | BM | 21.6 | 46,XY[20] | 2/24 (8) | 18q21 | 19/100 (19) | YGR |
| 21 | 67/F | G, κ | BM | 19.6 | 46,XX[20] | 1/14 (7) | Unknown | 10/100 (10) | YGR |
| 22 | 65/M | G, λ | BM | 19.2 | 46,XY[5] | ND | 17/100 (17) | YGR | |
| 23 | 76/F | G, λ | BM | 16.0 | 46,XX[5] | 2/20 (10) | Unknown | 10/100 (10) | YGR |
| 25 | 63/M | G, κ | BM | 15.2 | 46,XY[10] | 2/21 (10) | Unknown | 14/100 (14) | YGR |
| 24 | 61/F | G, κ | BM | 15.0 | 46,XX[20] | 4/16 (25) | 18q21 | 17/100 (17) | YGR |
| 26 | 75/F | G, λ | BM | 13.8 | ND | 1/7 (14) | Unknown | 11/100 (11) | YGR |
| 27 | 44/F | G, κ | BM | 13.2 | 46,XX[20] | 0/31 (0) | 10/100 (10) | YGR | |
| 28 | 82/F | G, λ | PE | 88.1 | Abnormal | 0/11 (0) | 1/100 (1) | ||
| 29 | 70/F | G, κ | BM | 59.2 | 46,XX[7] | 0/8 (0) | 6/100 (6) | ||
| 30 | 62/F | G, κ | BM | 17.4 | 46,XX[3] | ND | 4/100 (4) | ||
| 40.6ρ | |||||||||
| 31 | 54/M | G, κ | BM | 44.0 | t(8; 22) | 0/5 (0) | Unevaluable1-155 | ||
| 32 | 75/M | G, λ | BM | 43.0 | ND | 0/10 (0) | 1/50 (2) | ||
| 33 | 73/F | G, κ | BM | 36.4 | ND | ND | 5/100 (5) | ||
| 34 | 74/M | G, κ | BM | 33.6 | 46,XY[20] | 0/20 | 1/100 (1) | ||
| 35 | 81/M | G, κ | BM | 20.8 | 46,XY[5] | 0/11 (0) | 4/100 (4) | ||
| 36 | 65/M | G, λ | BM | 15.8 | 46,XY[20] | 0/15 (0) | 5/100 (5) | ||
| 37 | 62/M | G, κ | BM | 15.6 | 46,XY[22] | 0/26 (0) | 3/100 (3) | ||
| 38 | 60/M | G, κ | BM | 12.0 | 46,XY[18] | 0/4 (0) | 4/100 (4) | ||
| Plasma cell leukemia | |||||||||
| 39 | 66/M | G, κ | BM | 84.4 | 46,XY[5] | 4/6 (67) | 11q13 | 55/100 (55) | YGR |
| 401-154 | 79/F | BJ, (nonsecretary) | PB | 80.0 | 11q− | 3/5 (60) | 11q13 | 13/100 (13) | YYGG |
| 41 | 62/M | G, κ | PB | 28.0 | ND | 2/3 (67) | 11q13 | 15/100 (15) | YGR |
| Plasmacytoma | |||||||||
| 42 | 71/F | G, λ | BM | 19.8 | 46,XX[20] | 1/12 (8) | 11q13 | 8/50 (16) | YGR |
| MGUS | |||||||||
| 43 | 73/M | G, κ | BM | 9.6 | ND | 0/10 (0) | 18/200 (9) | YGR | |
| 44 | 73/M | G, λ | BM | 5.6 | Abnormal | 2/13 (15) | Unknown | 11/100 (11) | YGR |
| 45 | 78/M | G, λ | BM | 4.8 | 46,XY[20] | 0/14 (0) | 8/100 (8) | YGR | |
| 46 | 71/F | G, λ | BM | 8.8 | 46,XX[12] | 0/24 (0) | 3/100 (3) | ||
| 47 | 80/F | G, κ | BM | 1.6 | 46,XX[20] | 0/30 (0) | 4/100 (4) | ||
Abbreviations: s, split; PE, pleural effusion; ND, not done.
A karyotype was described in Table 2.
Donor sites were identified on the basis of the DAPI banding pattern.
Representative pattern of split signal was described.
ρ Plasmacytoid lymphocyte.
Interphase nuclei were unevaluable because of background noise in spite of repeated experiments.
Patient no. 40 showed complicated split signal pattern with yellow signals on the normal chromosome 14 and on the 11q− and green signals on the two marker chromosomes (YYGG pattern). Based on these findings, we counted nuclei carrying YYGG pattern and presented the number of positive nuclei in the table.